The study, which appears in Cancer Discovery, found that using this vaccine to target KRAS mutations produced a long-term immune response. This discovery could lead to a full-fledged strategy to prevent pancreatic cancer. This vaccine targeted the mutated protein, KRAS, which is found in the most common pancreatic cancer, pancreatic ductal adenocarcinoma (PDAC). Pancreatic cancer accounts for 8% of cancer deaths in the United States, and it is challenging to catch pancreatic cancer early . Finding ways to treat and potentially prevent pancreatic cancer is a critical area of ​​research.